Redmile Group LLC Has 6.40 Million Stake in AC Immune SA
| ACIU Stock | USD 2.68 0.02 0.74% |
Slightly above 61% of AC Immune's investor base is looking to short. The analysis of the overall investor sentiment regarding AC Immune suggests that many traders are alarmed. AC Immune's investing sentiment can be driven by a variety of factors including economic data, AC Immune's earnings reports, geopolitical events, and overall market trends.
ACIU |
Redmile Group LLC decreased its position in AC Immune SA by 6.3 percent during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities Exchange Commission. The firm owned 1,694,167 shares of the companys stock after selling 113,537 shares during the period. Redmile Group
Read at thelincolnianonline.com
 |
AC Immune Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards AC Immune can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
AC Immune Fundamental Analysis
We analyze AC Immune's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of AC Immune using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of AC Immune based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Revenue
Revenue Comparative Analysis
AC Immune is currently under evaluation in revenue category among its peers. Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
AC Immune Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with AC Immune stock to make a market-neutral strategy. Peer analysis of AC Immune could also be used in its relative valuation, which is a method of valuing AC Immune by comparing valuation metrics with similar companies.
Peers
AC Immune Related Equities
| FDMT | 4D Molecular | 9.17 | ||||
| SYBX | Synlogic | 3.65 | ||||
| OPT | Opthea | 3.41 | ||||
| STOK | Stoke Therapeutics | 3.36 | ||||
| PHVS | Pharvaris | 2.95 | ||||
| RGNX | Regenxbio | 2.83 | ||||
| IVVD | Invivyd | 2.33 | ||||
| BDTX | Black Diamond | 1.37 | ||||
| ABEO | Abeona Therapeutics | 1.24 | ||||
| PMVP | Pmv Pharmaceuticals | 0.67 | ||||
| MNOV | MediciNova | 0.46 | ||||
| ACRV | Acrivon Therapeutics, | 0.30 | ||||
| ANTX | AN2 Therapeutics | 0.79 | ||||
| AVTE | Aerovate Therapeutics | 1.17 | ||||
| ANEB | Anebulo Pharmaceuticals | 10.81 | ||||
| PEPG | PepGen | 11.25 |
Additional Tools for ACIU Stock Analysis
When running AC Immune's price analysis, check to measure AC Immune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AC Immune is operating at the current time. Most of AC Immune's value examination focuses on studying past and present price action to predict the probability of AC Immune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AC Immune's price. Additionally, you may evaluate how the addition of AC Immune to your portfolios can decrease your overall portfolio volatility.